Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline.
Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial designs by focusing on the right patient population(s) with the highest level of demonstrated real-world unmet need. The collaboration will center on powering research spanning Whitehawk Therapeutics' ADC portfolio, which includes three assets designed to target clinically validated proteins (PTK7, MUC16 and SEZ6) that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers.
"Tempus' comprehensive, multimodal data, paired with Whitehawk's ADC drug development expertise, create a powerful foundation to validate the potential of their portfolio in a promising class of targeted cancer therapeutics," said Ryan Fukushima, Chief Operating Officer at Tempus. "We're committed to working in tandem with our biotech collaborators to uncover actionable insights from our AI platform so they can make smarter, faster decisions throughout the drug development process."
"A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights," said Dave Lennon, PhD, President and CEO, Whitehawk Therapeutics. "By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline. An important aspect of this partnership will be continuing to establish the concordance between RNA and IHC expression of our targets. Because RNA testing is objective, reproducible and scalable, establishing it as a reliable alternative to the more subjective IHC methods could enhance our ability to readily identify appropriate patients for our ADC therapies."
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcome and benefits of the collaboration between Tempus and Whitehawk Therapeutics, as well as statements about improving trial design, patient selection, and the development of Whitehawk Therapeutics's ADC cancer therapies. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251016398546/en/
Hanah Heintzelman
[email protected]
